drugset / Trial / NCT04207255
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Phase 2
Completed
69 enrolled
Medical University of South Carolina
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase II study of the investigational drug opaganib. Patients with metastatic castration resistant prostate cancer (mCRPC) who have experienced disease progression while receiving abiraterone or enzalutamide will receive Opaganib at either 250 mg or 500 mg by mouth twice a day continuously. Patients will continue on study drug until the development of progressive disease, intolerable toxicity, withdrawal of patient consent or other event as outlined in patient discontinuation.
Timeline
- Start
- 2020-03-27
- Primary completion
- 2023-08-31
- Completion
- 2024-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABC294640 | Small molecule | 250 mg | Oral |
| Subject | ABC294640 | Small molecule | 500 mg | Oral |
| Background | Abiraterone acetate | Small molecule | — | Intravenous |
| Background | Enzalutamide | Other / unclassified | — | Intravenous |